Nose-to-Brain Targeting via Nanoemulsion: Significance and Evidence

Background: Non-invasive and patient-friendly nose-to-brain pathway is the best-suited route for brain delivery of therapeutics as it bypasses blood–brain barrier. The intranasal (olfactory trigeminal nerves) allows entry various bioactive agents, delivers a wide array hydrophilic hydrophobic drugs, circumvents hepatic first-pass effect, thus targeting neurological diseases in both humans animals. olfactory nerves make bridge between highly vascularised nasal cavity tissues permeation distribution, presenting direct into brain. Materials: This review portrays insight recent research reports (spanning last five years) on nanoemulsions developed actives management myriad disorders, namely, Parkinson’s disease, Alzheimer’s, epilepsy, depression, schizophrenia, cerebral ischemia tumours. information data are collected compiled from more than one hundred Scopus- PubMed-indexed articles. Conclusions: pathways facilitate better biodistribution bypass BBB issues and, thus, pose possible alternative hydrophobic, poor absorption enzyme degradative therapeutics. Exploring these virtues, have proven to be active, non-invasiveand safe brain-targeting cargos alleviation other neurodegenerative disorders.